The 9th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM)
In-Person Event
Oct 24 - 27, 2024
Berlin, Berlin, DE
13.5 CME 
OVERVIEW
The 9th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) is organized by CME Congresses Ltd and will be held from Oct 24 - 27, 2024 at Hotel nhow Berlin, Berlin, Berlin, Germany.
Description:
The COSTEM Congress is a platform for our community to interact with each other and to share our scientific research, clinical experience, and on-going developments in our field. COSTEM encourages active participation in debate discussions and challenges global experts to promote their positions on a wide range of burning issues – providing clinicians the opportunity to share, express and compare experiences in order to establish and advance effective and reliable patient treatments.
COSTEM 2024 will continue to push the envelope and be a progressive, compelling and informative congress, where the most compelling and controversial topics facing clinicians in our field are presented in a fascinating and exciting debate forum.
Main Topics:
• Acute leukemia
• Bi-specific antibodies
• CMV infection
• CAR T-cell therapy and cellular therapy
• Cord blood transplantation
• Donor lymphocyte infusion
• Drug conjugated antibodies
• Genome editing and gene therapy
• GvHD prevention and treatment
• Haploidentical stem cell transplantation
• Hodgkin and Non-Hodgkin lymphoma
• Mesenchymal stem cell
• Multiple myeloma
• Myeloproliferative neoplasm
• Myelodysplastic syndrome
• NK Cell therapy
• Pediatric indications for transplantation
• Relapse prevention
• Toxicity post transplantation (VOD, TMA, etc.)
• Transplant for severe aplastic anemia and hemoglobinopathies
• Virus specific T Cell therapy
Scientific Program:
| Thursday, October 24 | |
|---|---|
| 17:15-17:45 | Industry-supported Meet the Expert Session |
| 17:45-18:00 | Technical Break |
| 18:00-18:30 | ECP and Ruxolitinib combination in severe steroid-refractory acute GvHD Industry-supported Meet the Expert Session |
| Friday, October 25 | |
|---|---|
| 08:00-08:15 | Good Morning Coffee |
| 08:15-08:30 | Welcome Note Congress Co-Chairs |
| 08:30-10:00 | Session 1: Graft-versus-host disease (GvHD) Prophylaxis and Treatment |
| Controversy: Is Post-transplant cyclophosphamide (PTCy) or anti-thymocyte globulin (ATG) the current standard for GvHD prophylaxis in matched unrelated transplant? | |
| Moderator: Nicolaus Kröger, Germany | |
| 08:30-08:45 | PTCy: Leo Luznik, USA |
| 08:45-09:00 | ATG: Takanori Teshima, Japan |
| Controversy: Is Axatilimab becoming the new standard for chronic cGvHD? | |
| Moderator: Arnon Nagler, Israel | |
| 09:00-09:15 | Yes: Stephanie Lee, USA |
| 09:15-09:30 | No: Corey Cutler, USA |
| 09:30-10:00 | Panel discussion: All session faculty |
| 10:00-10:20 | Coffee Break, Poster Viewing and Visit Exhibition |
| 10:20-11:50 | Industry-supported Symposium |
| 11:50-12:00 | Technical Break |
| 12:00-13:30 | Session 2: Acute Myeloid Leukemia (AML) |
| Controversy: Should 5-Azacitidine venetoclax-based induction replace 7+3 induction in AML 50-65 years of age? | |
| Moderator: Andreas Burchert, Germany | |
| 12:00-12:15 | Yes: Thomas Schroeder, Germany |
| 12:15-12:30 | No: Lars Bullinger, Germany |
| Controversy: Should all FMS?like tyrosine kinase 3 (FLT3)-positive AML receive maintenance therapy post-allograft? | |
| Moderator: Lars Bullinger, Germany | |
| 12:30-12:45 | Yes: Andreas Burchert, Germany |
| 12:45-13:00 | No: Arnon Nagler, Israel |
| 13:00-13:30 | Panel discussion: All session faculty |
| 13:30-14:15 | Lunch Pick-up, Poster Viewing and Visit Exhibition |
| 14:15-15:15 | Industry-supported Lunch Symposium |
| 15:15-15:30 | Short Break |
| 15:30-17:00 | Session 3: Acute Lymphoblastic Leukemia (ALL) |
| Controversy: Should we include short-course blinatumomab in adult ALL patients with minimal residual disease (MRD) pre allogeneic stem cell transplantation (allo-SCT)? | |
| Moderator: Matthias Stelljes, Germany | |
| 15:30-15:45 | Yes: Nicola Gökbuget, Germany |
| 15:45-16:00 | No: Sebastian Giebel, Poland |
| Controversy: Are we ready for total body irradiation (TBI)-free conditioning in adult ALL | |
| Moderator: Sebastian Giebel, Poland | |
| 16:00-16:15 | Yes: Avichai Shimoni, Israel |
| 16:15-16:30 | No: Matthias Stelljes, Germany |
| 16:30-17:00 | Panel discussion: All session faculty |
| 17:00-17:30 | Coffee Break, Poster Viewing and Visit Exhibition |
| 17:30-19:00 | Session 4: Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) |
| Controversy: Are we ready for molecular prognostication for transplant decision making in MDS? | |
| Moderator: Nicolaus Kröger, Germany | |
| 17:30-17:45 | Yes: Carmelo Gurnari, Italy |
| 17:45-18:00 | No: Fernando Barroso Duarte, Brazil |
| Controversy: Are we ready for molecular prognostication for transplant decision making in MPN? | |
| Moderator: Avichai Shimoni, Israel | |
| 18:00-18:15 | Yes: Nico Gagelmann, Germany |
| 18:15-18:30 | No: Donal McLornan, UK |
| 18:30-19:00 | Panel discussion: All session faculty |
| Saturday, October 26 | |
|---|---|
| 08:30-10:00 | Session 5: Lymphoma and Myeloma |
| Controversy: Can we replace autologous stem-cell transplantation (auto-SCT) for multiple myeloma by CAR T or bispecific antibodies? | |
| Moderator: Claudio Cerchione, Italy | |
| 08:30-08:45 | Yes: TBA |
| 08:45-09:00 | No: Maximilian Merz, Germany |
| Controversy: Do we abandon allo-SCT for Non-Hodgkin’s lymphoma? | |
| Moderator: Nico Gagelmann, Germany | |
| 09:00-09:15 | Yes: Anna Sureda, Spain |
| 09:15-09:30 | No: Ali Bazarbachi, Lebanon |
| 09:30-10:00 | Panel discussion: All session faculty |
| 10:00-10:30 | Coffee Break, Poster Viewing and Visit Exhibition |
| 10:30-12:00 | Session 6: GvHD Prevention and Treatment |
| Controversy: Is abatacept the new standard for matched and mismatched unrelated donor SCT? | |
| Moderator: Corey Cutler, USA | |
| 10:30-10:45 | Yes: Robert Soiffer, USA |
| 10:45-11:00 | No: Francesca Bonifazi, Italy |
| Controversy: Are mesenchymal stem cells (MSC) an alternative to ruxolitinib in SR GvHD? | |
| Moderator: Francis Ayuk, Germany | |
| 11:00-11:15 | Yes: Peter Bader, Germany |
| 11:15-11:30 | No: Hildegard Greinix, Austria |
| 11:30-12:00 | Panel discussion: All session faculty |
| 12:00-12:45 | Lunch Pick-up, Poster Viewing and Visit Exhibition |
| 12:45-14:15 | Industry-supported Lunch Symposium |
| 14:15-14:30 | Short Break |
| 14:30-16:00 | Session 7: Non-malignancies |
| Controversy: Are we ready for haploidentical stem cell transplantation (haplo-SCT) upfront as routine practice in severe aplastic anemia (SAA)? | |
| Moderator: Emanuele Angelucci, Italy | |
| 14:30-14:45 | Yes: Carlo Dufour, Italy |
| 14:45-15:00 | No: Antonio Risitano, Italy |
| Controversy: Haplo-SCT vs gene therapy in sickle cell disease (SCD) | |
| Moderator: Franco Locatelli, Italy | |
| 15:00-15:15 | Haplo-SCT: Emanuele Angelucci, Italy |
| 15:15-15:30 | Gene therapy: Markus Mapara, USA |
| 15:30-16:00 | Panel discussion: All session faculty |
| 16:00-16:30 | Coffee Break, Poster Viewing and Visit Exhibition |
| 16:30-17:30 | Session 8: Myths and Facts around EBV post HSCT |
| A series of statements and disucssion Moderator: Jan Styczynski, Poland | |
| 16:30-16:40 | Statement: There is a threshold for EBV PCR in blood starting treatment with Anti CD20 antibodies Facts, presented by: Marcos de Lima, USA |
| 16:40-16:50 | Statement: EBV specific T cells are the treatment of choice for EBV reactivation and EBV related PTLD Facts, presented by: Guenther Koehne, USA |
| 16:50-17:00 | Statement: EBV serostatus predicts outcome after allogeneic HSCT Facts, presented by: Jan Styczynski, Poland |
| 17:00-17:30 | Panel discussion: All session faculty |
| 17:30-17:45 | Short Break |
| 17:45-19:15 | Session 9: Pediatrics |
| Controversy: Do we need allogeneic HSCT consolidation after CD19 CAR T therapy for pediatric ALL? | |
| Moderator: Krzysztof Kalwak, Poland | |
| 17:45-18:00 | Yes: Peihua Lu, China |
| 18:00-18:15 | No: André Baruchel, France |
| Controversy: ?? T cells T cell depletion Haplo-SCT vs non T cell depletion Haplo-SCT in pediatric malignancies | |
| Moderator: Emanuele Angelucci, Italy | |
| 18:15-18:30 | ?? T cells T cell depletion: Franco Locatelli, Italy |
| 18:30-18:45 | Non T cell depletion: Krzysztof Kalwak, Poland |
| 18:45-19:15 | Panel discussion: All session faculty |
| 19:15 | Poster Walk and Awards Session (Poster Area) |
| Sunday, October 27 | |
|---|---|
| 09:00-10:30 | Session 10: Artificial Intelligence (AI) and Specific Cell Therapy |
| Controversy: Are we ready for prediction of transplant-related complication including GvHD by machine-learning and AI? | |
| Moderator: Alessandro Rambaldi, Italy | |
| 09:00-09:15 | Yes: Roni Shouval, USA |
| 09:15-09:30 | No: Francis Ayuk, Germany |
| 09:30-09:45 | Discussion |
| Controversy: Will cytotoxic T lymphocytes (CTL)s become a standard option for post-transplant infection? | |
| Moderator: Lori Muffly, USA | |
| 09:45-10:00 | Yes: Britta Eiz-Vesper, Germany |
| 10:00-10:15 | No: Rafael de la Cámara, Spain |
| 10:15-10:30 | Discussion |
| 10:30-11:00 | Coffee Break |
| 11:00-12:30 | Session 11: Graft Manipulation and Autoimmune Diseases |
| Controversy: Are we back to graft manipulation in allogeneic transplantation? | |
| Moderator: Nicolaus Kröger, Germany | |
| 11:00-11:15 | Yes: Lori Muffly, USA |
| 11:15-11:30 | No: Alessandro Rambaldi, Italy |
| 11:30-11:45 | Discussion |
| Controversy: Do CAR T cells replace autologous SCT in autoimmune disease? | |
| Moderator: Arnon Nagler, Israel | |
| 11:45-12:00 | Yes: Fabian Müller, Germany |
| 12:00-12:15 | No: Raffaella Greco, Italy |
| 12:15-12:30 | Discussion |
| 12:30 | Closing remarks Congress Co-Chairs |
KEY DATES
24 Oct, 2024
Event Start Date
27 Oct, 2024
Event End Date
ACCREDITATION & CREDITS
EBAH CME Accreditation:
The EBAH- CME Unit has approved this educational activity for a maximum number of CME credits. Each physician should only claim credits for time that she/he actually spent in the educational activity. We are pleased to inform you that the 2024 COSTEM Congress has been awarded:
- 13.5 EBAH-CME Credit Points
All participants may print a European Board for Accreditation in Hematology (EBAH) CME certificate indicating the number of EBAH-CME Credit Points awarded, directly from the system on the CME section of the EBAH website.
AEKB CME Accreditation:
The 9th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) has been accredited by the Berlin Chamber of Physicians (Ärzetkammer Berlin) for a maximum of
- 12 CME credits
Day 1 (October 25): 6 CME credits, Category B
Day 2 (October 26): 6 CME credits, Category B
Each medical specialist should claim only those days of credit that they actually spent in the educational activity. The Berlin Chamber of Physicians’ CMEC credit system is based on 1 CMEC per 45 minutes.
TARGET AUDIENCE
PhysicianScientistsStudentsOncologistsResidentsNursesHematologistTraineesSPECIALITIES
HaematologyCell and Developmental BiologyHematology Blood and Marrow TransplantPediatric Hematology and Bone Marrow TransplantOncologySUGGESTED HOTELS
CONFERENCE VENUE
Hotel nhow BerlinCANCELLATION & REFUND POLICY
Cancellation Policy:
All cancellations must be faxed, electronically mailed or postmarked. Refund of registration fees will be as follows:
Postmarked up until September 1, 2024 – 100% refund (minus € 50 handling fee and bank charges)
Postmarked from September 2, 2024 – 50% refund
No refund on cancellations sent after October 10, 2024
RELATED CONFERENCES & LIVE WEBINARS
By United Research Forum (URF)
Oct 26 - 27, 2026 | Paris, ...
Molecular Biology
By United Research Forum (URF)
Oct 29 - 30, 2026 | Orlando, Florida, USA
Oncology
Quick Links